Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results

Journal of Rheumatology

Volumn 40, Issue 2, 2013, Pages 113-126

  Fleischmann, Roy M ^a,g   Halland, Anne Marie ^b   Brzosko, Marek ^c   Burgos Vargas, Ruben ^d   Mela, Christopher ^e   Vernon, Emma ^e   Kremer, Joel M ^f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Panorama Medi Clinic   (South Africa)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d HOSPITAL GENERAL DE MÉXICO   (Mexico)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f Center for Rheumatology LLP   (United States)

^g METROPLEX CLINICAL RESEARCH CENTER   (United States)

Author keywords

Biological products; Interleukins; Randomized control trial; Rheumatoid arthritis

Indexed keywords

METHOTREXATE; PLACEBO; TOCILIZUMAB;

ACCIDENT; ACUTE HEART INFARCTION; ADULT; ALCOHOL INTOXICATION; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANKLE FRACTURE; ANUS CANCER; ARTICLE; BASAL CELL CARCINOMA; BLOOD CHEMISTRY; BONE MARROW DEPRESSION; BREAST CANCER; BRONCHITIS; CELLULITIS; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; COMPRESSION FRACTURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEMALE; GASTROENTERITIS; GASTROESOPHAGEAL CANCER; GENANT MODIFIED TOTAL SHARP SCORE; GENITAL BLEEDING; HEALTH ASSESSMENT QUESTIONNAIRE; HEART VENTRICLE FIBRILLATION; HEMOPTYSIS; HERPES ZOSTER; HIATUS HERNIA; HUMAN; HYPERTENSION; HYPOTENSION; INTERVERTEBRAL DISK HERNIA; INTESTINE ULCER; JAW CYST; JOINT DESTRUCTION; KIDNEY CARCINOMA; KIDNEY FAILURE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTATIC MELANOMA; MULTICENTER STUDY; NEUTROPHIL COUNT; OPEN STUDY; PHYSICAL CAPACITY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SKIN CANCER; SKIN CARCINOMA; SPINE FRACTURE; SPONTANEOUS ABORTION; THYROID CANCER; TONGUE CANCER; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA; VASCULITIS; VIRAL GASTROENTERITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 84873600423     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120447     Document Type: Article

References (29)

1. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731-40.
2. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003;48:1521-9.
3. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: Role in inflammation and cancer. J Leukoc Biol 2006;80:227-36.
4. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
5. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96.
6. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
7. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58:2968-80.
8. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9.
9. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
10. Bykerk V, Ostor AJK, Alvaro-Gracia J, Pavelka K, Roman-Ivorra J, Graninger W, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: A large, open-label study close to clinical practice. Ann Rheum Dis 2012 Jul 6. [E-pub ahead of print]
11. Kremer JM, Blanco R, Brzosko S, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
12. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006;8:S3.
13. Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983;75:35-47.
14. Harris C, Billisberger K, Tillotson L, Peters S, Pederson C, Becker M. Injection site pain: Interferon beta-1b versus interferon beta-1a. Presented at: The Challenges of Care and Research in Multiple Sclerosis 18th Annual Meeting; June 2-6, 2004; Toronto, Canada.
15. Felson DT, Anderson JJ, Lange MLM, Wells G, La Valley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
16. Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
17. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90.
18. Hillman RS, Ault KA, Rinder HM. Normal myelopoiesis. In: Hematology in clinical practice: A guide to diagnosis and management. 4th ed. New York: McGraw Hill; 2005:173-85.
19. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50:1400-11.
20. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594-602.
21. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108.
22. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
23. Combe B. Impact of dosing on treatment with TNF inhibitors: managing dose adjustment. Clin Exp Rheumatol 2010;28 Suppl 59:S13-S17.
24. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004;363:675-81.
25. van Vollenhoven RF, Scali J, Curtis JR, Krasnow J, Vernon E, Alten R. Safety of tocilizumab in patients with rheumatoid arthritis: Analysis of median of 2.6 years of treatment in long-term extension studies [abstract]. Ann Rheum Dis 2010;69:544.
26. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:2368-76.
27. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
28. Fleischmann RM, Blanco R, Castelar-Pinheiro G, Vernon E, Mela C, Kremer JM. Tocilizumab (TCZ) plus methotrexate (MTX) in rheumatoid arthritis (RA) patients (pts) who increased TCZ dose from 4 mg/kg to 8 mg/kg: LITHE radiographic and safety data [abstract]. Arthritis Rheum 2010;62 Suppl:S951.
29. Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: An epidemiological assessment. Ann Rheum Dis 2009;68:1819-26.